This article aims to review the available literature for tumefactive demyelination ... the diagnosis of multiple sclerosis ...

The process affects peripheral nerves in various forms of polyneuritis, and the central nervous system in multiple (disseminated) sclerosis. The effects of demyelination on conduction in the ...

Multiple sclerosis, the prototype of demyelinating ... the physiology of nerve impulse propagation before and after CNS demyelination. This emphasis on neurophysiological analysis of nerve ...

PTD802 is a selective inhibitor of the GPR17 receptor and is made to restore myelin, a process known as remyelination, in ...

Nowadays, multiple sclerosis relapses can be completely and safely eliminated in most patients, and the more treatment-resistant ...

Optic Neuritis: Clinical Features Optic neuritis refers to inflammation of the optic nerve. The term may be used broadly in reference to many causes of optic nerve inflammation including systemic ...

The objective was to describe in multiple sclerosis ... an acute episode of inflammatory demyelination. Contrapulsion is an ...

Multiple sclerosis (MS) is a neurodegenerative disease that causes demyelination of the CNS. MS can cause a wide variety of neuro-ophthalmic manifestations and is also associated in some cases ...

Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics ...

Pheno Therapeutics has gained clinical trial authorisation (CTA) from the UK's MHRA for its small molecule therapeutic, ...

Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics ...

UK MHRA grants CTA for first-in-human trial of a selective GPR17 antagonist Small molecule therapeutic designed for treatment of neurological diseases such as multiple sclerosis Pheno Therapeutics ...